NCT01173497

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Study identifier: NCT01173497
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Iniparib (Sanofi Aventis)

Eligibility:

Triple-negative breast cancer with brain lesion on radiographic imaging

Type of study:

Phase II study

Treatment:

Participants receive a combination of iniparib and irinotecan

Study sites:

District of Columbia

Georgetown University 
Washington, District of Columbia
Contact: Antonella Novielli, RN     202-784-3923       

Illinois

University of Chicago   
Chicago, Illinois
Contact: Ashley Nurthussein     773-834-9774       

Indiana

Indiana University Simon Cancer Center           
Indianapolis, Indiana
Contact: Sara Singleton, RN     317-274-8136       

Michigan

University of Michigan  
Ann Arbor, Michigan, United States
Contact: Catherine Van Poznak, MD     734-936-9209       

North Carolina

University of North Carolina-CH Lineberger Comprehensive Cancer Center        
Chapel Hill, North Carolina 27599-7295
Contact:  Madlyn Ferraro     919-966-7359     beelerm@med.unc.edu   
Contact:  Maureen Beeler         beelerm@med.unc.edu   

Duke University
Durham, North Carolina
Contact: Dana Fifield, RN     919-660-1278    

Page updated 03/21/11    

Web design by Rareheron Web Design